Humana price target raised to $330 from $312 at BofA

BofA analyst Kevin Fischbeck raised the firm’s price target on Humana (HUM) to $330 from $312 and keeps a Neutral rating on the shares. The firm views UnitedHealth’s (UNH) Medicare Advantage stars data yesterday as positive for investor sentiment in the managed care group. As a result, BofA is assigning a higher peer multiple for Humana shares. However, an uncertain 2027 Medicare Advantage rate outlook could delay am earnings rebound, the analyst tells investors in a research note.